ANI to buy Egetis for ~$560M cash offer at 27% premium; EMCITATE peak sales seen above $300M

ANI PHARMACEUTICALS INC

• SEK 11.25 per share cash offer values Egetis at ~SEK 5.6B ($559.9M), a 27% premium to the 60-day VWAP; enterprise value ~$434M after Egetis' $190M priority review voucher sale.
• Egetis board unanimously recommends; holders of ~42.2% of outstanding shares signed irrevocables; closing needs 90% tendered plus regulatory/FDI clearances, acceptance period ~Nov 20-Dec 18, 2026.
• EMCITATE (tiratricol) is the first and only approved MCT8 deficiency treatment - EU approval Feb 12, 2025, FDA Sept 28, 2026 - with >$300M peak sales potential and protection into mid-2045.
• $676M 364-day senior bridge from JPMorgan (ABR+1.75%, adjusted SOFR+2.75%) funds the offer and refinances ANI's existing term loans and Egetis debt; initially unsecured, then guaranteed/secured.
• ANI reports 3Q 2026 results the same morning ahead of an 8:00 a.m. ET call; Jefferies is ANI's sole financial advisor, Centerview advises Egetis, with Ropes & Gray and Mannheimer Swartling as counsel.